Bivalirudin vs Heparin in Patients Who Undergo Transcatheter Aortic Valve Implantation

Canadian Journal of Cardiology

Volumn 31, Issue 8, 2015, Pages 998-1003

  Lange, Philipp ^a   Greif, Martin ^a   Bongiovanni, Dario ^a,b,c   Thaumann, Antonia ^a   Näbauer, Michael ^a   Bischoff, Bernhard ^a   Helbig, Susanne ^a   Becker, Christoph ^a   Schmitz, Christoph ^a   D'Anastasi, Melvin ^a   Mehilli, Julinda ^a,c   Boekstegers, Peter ^d   Massberg, Steffen ^a,c   Kupatt, Christian ^a,b,c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^d Heart Center Siegburg   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; HIRULOG; ANTICOAGULANT AGENT; ANTITHROMBIN; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ACUTE KIDNEY FAILURE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS AORTIC VALVE; POSTOPERATIVE PERIOD; SURGICAL MORTALITY; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT OUTCOME; VERY ELDERLY; AORTIC VALVE STENOSIS; COMPARATIVE STUDY; FOLLOW UP; RETROSPECTIVE STUDY; THROMBOSIS;

AGED, 80 AND OVER; ANTICOAGULANTS; ANTITHROMBINS; AORTIC VALVE STENOSIS; FEMALE; FOLLOW-UP STUDIES; HEPARIN; HIRUDINS; HUMANS; MALE; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THROMBOSIS; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME;

EID: 84937718304     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2015.02.029     Document Type: Article

References (19)

1. Kodali S.K., Williams M.R., Smith C.R., et al. Two-year outcomes after transcatheter or surgical aortic-valve replacement. NEngl J Med 2012, 366:1686-1695.
2. Adams D.H., Popma J.J., Reardon M.J., et al. Transcatheter aortic-valve replacement with a self-expanding prosthesis. NEngl J Med 2014, 370:1790-1798.
3. Genereux P., Cohen D.J., Williams M.R., et al. Bleeding complications after surgical aortic valve replacement compared with transcatheter aortic valve replacement: insights from the PARTNER I trial (Placement of Aortic Transcatheter Valve). JAm Coll Cardiol 2014, 63:1100-1109.
4. Linke A., Wenaweser P., Gerckens U., et al. Treatment of aortic stenosis with a self-expanding transcatheter valve: the International Multi-centre ADVANCE Study. Eur Heart J 2014, 35:2672-2684.
5. Eggebrecht H., Schmermund A., Voigtl T., Kahlert P., Erbel R., Mehta R.H. Risk of stroke after transcatheter aortic valve implantation (TAVI): a meta-analysis of 10,037 published patients. EuroIntervention 2012, 8:129-138.
6. Nikolsky E., Stone G.W. Antithrombotic strategies in non-ST elevation acute coronary syndromes: focus on bivalirudin. Future Cardiol 2007, 3:345-364.
7. Kastrati A., Neumann F.J., Schulz S., et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. NEngl J Med 2011, 365:1980-1989.
8. Kelly D.J., Gershlick T., Witzenbichler B., et al. Incidence and predictors of heart failure following percutaneous coronary intervention in ST-segment elevation myocardial infarction: the HORIZONS-AMI trial. Am Heart J 2011, 162:663-670.
9. Kini A., Yu J., Cohen M.G., et al. Effect of bivalirudin on aortic valve intervention outcomes study: a two-centre registry study comparing bivalirudin and unfractionated heparin in balloon aortic valvuloplasty. EuroIntervention 2014, 10:312-319.
10. Greif M., Lange P., Nabauer M., et al. Transcutaneous aortic valve replacement with the Edwards SAPIEN XT and Medtronic CoreValve prosthesis under fluoroscopic guidance and local anaesthesia only. Heart 2014, 100:691-695.
11. Durand E., Borz B., Godin M., et al. Transfemoral aortic valve replacement with the Edwards SAPIEN and Edwards SAPIEN XT prosthesis using exclusively local anesthesia and fluoroscopic guidance: feasibility and 30-day outcomes. JACC Cardiovasc Interv 2012, 5:461-467.
12. Leon M.B., Smith C.R., Mack M., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. NEngl J Med 2010, 363:1597-1607.
13. Kappetein A.P., Head S.J., Genereux P., et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. JAm Coll Cardiol 2012, 60:1438-1454.
14. Sellers R.D., Levy M.J., Amplatz K., Lillehei C.W. Left retrograde coronarangiography in acquired cardiac disease: technic, indications and interpretations in 700 cases. Am J Cardiol 1964, 14:437-447.
15. O'Neill B., Singh V., Kini A., et al. The use of vascular closure devices and impact on major bleeding and net adverse clinical events (NACEs) in balloon aortic valvuloplasty: a sub-analysis of the BRAVO study. Catheter Cardiovasc Interv 2014, 83:148-153.
16. Goebel N., Baumbach H., Ahad S., et al. Transcatheter aortic valve replacement: does kidney function affect outcome?. Ann Thorac Surg 2013, 96:507-512.
17. Sergie Z., Lefevre T., Van Belle E., et al. Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies. JThromb Thrombolysis 2013, 35:483-493.
18. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. NEngl J Med 2006, 355:2203-2216.
19. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. NEngl J Med 2008, 358:2218-2230.